CN103119030A - 基质金属蛋白酶抑制剂 - Google Patents

基质金属蛋白酶抑制剂 Download PDF

Info

Publication number
CN103119030A
CN103119030A CN2011800461515A CN201180046151A CN103119030A CN 103119030 A CN103119030 A CN 103119030A CN 2011800461515 A CN2011800461515 A CN 2011800461515A CN 201180046151 A CN201180046151 A CN 201180046151A CN 103119030 A CN103119030 A CN 103119030A
Authority
CN
China
Prior art keywords
compound
phenyl
oxo
phentriazine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800461515A
Other languages
English (en)
Chinese (zh)
Inventor
M·K·凯拉
J·萨提盖利
V·萨提盖利
N·K·亚达夫
K·库马
A·R·A·拉夫
I·A·克利夫
P·K·巴特纳格尔
A·雷
P·斯里瓦斯塔瓦
S·G·达斯蒂达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CN103119030A publication Critical patent/CN103119030A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
CN2011800461515A 2010-07-30 2011-07-14 基质金属蛋白酶抑制剂 Pending CN103119030A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1810/DEL/2010 2010-07-30
IN1810DE2010 2010-07-30
PCT/IB2011/053155 WO2012014114A1 (en) 2010-07-30 2011-07-14 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
CN103119030A true CN103119030A (zh) 2013-05-22

Family

ID=44720049

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800461515A Pending CN103119030A (zh) 2010-07-30 2011-07-14 基质金属蛋白酶抑制剂

Country Status (11)

Country Link
EP (1) EP2598493A1 (pt)
JP (1) JP2013537533A (pt)
KR (1) KR20130042590A (pt)
CN (1) CN103119030A (pt)
AU (1) AU2011284397A1 (pt)
BR (1) BR112013002370A2 (pt)
CA (1) CA2807097A1 (pt)
CO (1) CO6680674A2 (pt)
MX (1) MX2013001240A (pt)
SG (1) SG187654A1 (pt)
WO (1) WO2012014114A1 (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103254290A (zh) * 2013-05-30 2013-08-21 苏州普罗达生物科技有限公司 基质金属蛋白酶-2多肽抑制剂及其应用
CN103304634A (zh) * 2013-05-30 2013-09-18 苏州普罗达生物科技有限公司 基质金属蛋白酶-2多肽抑制剂及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015150366A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Cyclisch substituierte phenolether-derivate und ihre verwendung
WO2015150350A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
WO2015150364A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituierte benzotriazinonbutansäuren und ihre verwendung
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015189117A1 (de) * 2014-06-12 2015-12-17 Bayer Pharma Aktiengesellschaft Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3700681A (en) 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4011258A (en) 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
CY1273A (en) 1980-07-09 1985-03-08 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
IL151250A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Difluorobutyric acid metalloprotease inhibitors
CA2433516A1 (en) 2001-01-30 2002-08-08 Keith Michael Devries Processes for preparing chromanylbenzoic acids
US6794510B2 (en) 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
ES2381681T3 (es) 2005-02-22 2012-05-30 Ranbaxy Laboratories Limited Derivados de ácido 5-fenil-pentanoico como inhibidores de la metaloproteinasa matriz para el tratamiento del asma y otras enfermedades
CN101528691B (zh) 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103254290A (zh) * 2013-05-30 2013-08-21 苏州普罗达生物科技有限公司 基质金属蛋白酶-2多肽抑制剂及其应用
CN103304634A (zh) * 2013-05-30 2013-09-18 苏州普罗达生物科技有限公司 基质金属蛋白酶-2多肽抑制剂及其应用

Also Published As

Publication number Publication date
WO2012014114A1 (en) 2012-02-02
BR112013002370A2 (pt) 2017-06-20
KR20130042590A (ko) 2013-04-26
JP2013537533A (ja) 2013-10-03
AU2011284397A1 (en) 2013-02-21
SG187654A1 (en) 2013-03-28
CA2807097A1 (en) 2012-02-02
MX2013001240A (es) 2013-08-27
EP2598493A1 (en) 2013-06-05
CO6680674A2 (es) 2013-05-31

Similar Documents

Publication Publication Date Title
CN103119030A (zh) 基质金属蛋白酶抑制剂
EP3100727B1 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CN103228634A (zh) 基质金属蛋白酶抑制剂
CN101616925B (zh) 三环化合物及其作为糖皮质激素受体调节剂的用途
CN103140479B (zh) 制造嘧啶衍生物的方法
TW200413331A (en) Small molecule PI 3-kinase inhibitors and methods of their use
CN105727298A (zh) 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
CN105130957A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
CN101124201A (zh) Parp抑制剂
CN103249719A (zh) 基质金属蛋白酶抑制剂
CN103391932B (zh) 用于抑制pask的杂环化合物
CN101500997A (zh) Parp抑制剂
WO2011035174A1 (en) Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
EP2460804A1 (en) 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
CN101490030A (zh) 新的苯并吡喃和1,2-苯并硫吡喃酰胺衍生物，其制备方法和治疗应用
CN103402995A (zh) 新型吲哚、吲唑衍生物或其盐
JP2023518356A (ja) Ｃｏｖｉｄ－１９関連状態の治療のための方法
WO1990012001A1 (fr) Derives de thionaphthalenes, procede pour leur production, et agent anti-allergique en contenant
CN101287712B (zh) 杂环化合物
JP2001151742A (ja) アニリド誘導体及びそれを含有する抗不整脈剤
CN105085436A (zh) 磺酰胺类衍生物及其在药物上的应用
JP2004520399A (ja) トロンビン阻害剤
JP2002513789A (ja) １−（６−クロロナフト−２−イルスルホニル）−４−［４−（４−ピリジル）ベンゾイル］ピペラジンの細かい粒子サイズ形
CN102666528A (zh) 晶体cdc7 抑制剂盐
CN101304979A (zh) 喹唑啉衍生物及医药品

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130522

WD01 Invention patent application deemed withdrawn after publication